AQST
Aquestive Therapeutics, Inc.
AQST lost money over the past year, so it has no meaningful PE right now.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AQST Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
AQST's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AQST PE Valuation
AQST has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AQST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
AQST has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AQST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.64 | +$0.06 |
| Q2 2026 | -$0.65 | +$0.04 |
| Q1 2026 | -$0.61 | -$0.03 |
| Q4 2025 | -$0.78 | -$0.27 |
| Q3 2025 | -$0.70 | -$0.26 |
| Q2 2025 | -$0.69 | -$0.35 |
| Q1 2025 | -$0.58 | -$0.17 |
| Q4 2024 | -$0.51 | -$0.38 |
AQST is still losing money, but far less than before: $0.64 per share over the past year, against $2.63 at its worst in late 2019.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over AQST on earnings, with more consistent year-over-year improvement.
AQST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.6M | -41% |
| Q2 2026 | $13.8M | +38% |
| Q1 2026 | $14.4M | +66% |
| Q4 2025 | $13M | +9.7% |
| Q3 2025 | $12.8M | -5.4% |
| Q2 2025 | $10M | -50% |
| Q1 2025 | $8.7M | -28% |
| Q4 2024 | $11.9M | -10% |
AQST's revenue is growing: $8M last quarter, down 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -191% | -102 points |
| Q2 2026 | -60% | +54 points |
| Q1 2026 | -29% | +193 points |
| Q4 2025 | -222% | -107 points |
| Q3 2025 | -90% | -28 points |
| Q2 2025 | -114% | -114 points |
| Q1 2025 | -222% | -148 points |
| Q4 2024 | -114% | -85 points |
AQST's operating margin was −191% last quarter, down 102 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AQST on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over AQST on profitability, with a higher operating margin.
AQST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.6M | +$5.3M |
| Q2 2026 | -$9.7M | -$1.6M |
| Q1 2026 | -$14.9M | +$8.7M |
| Q4 2025 | -$8.6M | -$2.1M |
| Q3 2025 | -$12.9M | -$924K |
| Q2 2025 | -$8M | -$980K |
| Q1 2025 | -$23.5M | -$13.1M |
| Q4 2024 | -$6.5M | -$1.5M |
AQST has burned cash in almost every quarter: −$41M over the past year, against −$51M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AQST on cash generation, producing positive trailing cash flow while its opponent burns cash.
AQST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +555K shares |
| 1 year | +14% | +15M shares |
| 3 years | +94% | +60.9M shares |
| 5 years | +220% | +86.3M shares |
| Available history | +274% | +92M shares |
AQST has 126M diluted shares, up 14% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AQST on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AQST Net Leverage
AQST's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AQST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.3 | Neutral |
| Stochastic | 9.9 | Oversold |
AQST's weekly RSI is 40 (neutral) and its Stochastic is 10 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AQST PE vs Healthcare Sector
AQST has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AQST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.11 | 13% below |
| 20 week MA | $4.26 | 16% below |
| 50 week MA | $4.32 | 17% below |
| 100 week MA | $4.14 | 14% below |
| 200 week MA | $3.42 | 4.4% above |
AQST has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AQST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.54 | $6.37 | +15% |
| 2021 | $6.37 | $4.03 | -37% |
| 2022 | $4.03 | $0.93 | -77% |
| 2023 | $0.93 | $2.02 | +117% |
| 2024 | $2.02 | $3.52 | +74% |
| 2025 | $3.52 | $5.99 | +70% |
| 2026 YTD | $5.99 | $3.57 | -40% |
AQST has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.